Boston Scientific Corporation
—- Market cap
- —
- Debt
- +$11.44B
- Cash
- −$1.97B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $2.74B · View financials
Decision snapshot: BSX stock price vs FCPT: inconclusive — current versus $44.46 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FCPT's multiple
Implied fair value · at BSX's multiple
Needs BSX P/E.
Snapshot Sep 8, 9:59 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BSX FY 2025 (ended Dec 31, 2025) · FCPT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 69% equity / 31% debt · EV / Revenue 13.37x · EV / EBITDA 17.43x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BOSTON SCIENTIFIC CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Four Corners Property Trust, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.47x
0.74x
Net debt / EBITDA
Leverage against operating earnings
1.75x
5.28x
Cash and equivalents
Liquid reserves on the balance sheet
$1.97B
$12.14M
Total debt
Interest-bearing obligations outstanding
$11.44B
$1.20B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Abbott Laboratories
BSX vs ABT
Johnson & Johnson
BSX vs JNJ
Intuitive Surgical, Inc.
BSX vs ISRG
STRYKER CORP
BSX vs SYK
ZIMMER BIOMET HOLDINGS, INC.
BSX vs ZBH
Edwards Lifesciences Corp
BSX vs EW
REALTY INCOME CORP
BSX vs O
AGREE REALTY CORP
BSX vs ADC
GETTY REALTY CORP /MD/
BSX vs GTY
ESSENTIAL PROPERTIES REALTY TRUST, INC.
BSX vs EPRT
STAG Industrial, Inc.
BSX vs STAG
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.